NCT05058014
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Drug Category: Other
Key Eligibility Criteria:
Gender: All
Age: 22 Years and older (Adult, Older Adult)
Location of Metastases: Bone
Additional Notes:
Exclusions: Patients with asymptomatic bone lesions that do note require an intervention
https://ClinicalTrials.gov/show/NCT05058014